Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
This article was originally published in The Pink Sheet Daily
Executive Summary
Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.
You may also be interested in...
Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.
Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.
HGS Submits BLA For Interferon Zalbin For Hepatitis C
If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.